Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H J Dubbink

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Gene|November 28, 1996
The aroA gene of Campylobacter jejuniM M Wösten, H J Dubbink, B A van der Zeijst
Nucleic Acids Research|November 25, 1993
Single point mutations in domain II of the yeast mitochondrial release factor mRF-1 affect ribosome bindingH J Pel, M Rep, H J Dubbink, et al.
Gene|December 2, 1999
An Sp1 binding site is essential for basal activity of the human prostate-specific transglutaminase gene (TGM4) promoterH J Dubbink, K B Cleutjens, H A van der Korput, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 6, 1999
Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution patternH J Dubbink, R F Hoedemaeker, T H van der Kwast, et al.
The Biochemical Journal|May 1, 1996
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminaseH J Dubbink, N S Verkaik, P W Faber, et al.
Genomics|August 29, 1998
The human prostate-specific transglutaminase gene (TGM4): genomic organization, tissue-specific expression, and promoter characterizationH J Dubbink, L de Waal, R van Haperen, et al.
Urology|May 20, 1998
Expression of prostatic factors measured by reverse transcription polymerase chain reaction in human papillomavirus type 18 deoxyribonucleic acid immortalized prostate cell linesP C Weijerman, Y Zhang, J Shen, et al.
The British Journal of Ophthalmology|October 31, 2020
Prognostic value of <i>TERT</i> promoter mutations in conjunctival melanomas in addition to clinicopathological featuresJ A van Ipenburg, N C Naus, H J Dubbink, et al.
Journal of Medical Genetics|February 17, 2026
End of a diagnostic odyssey: the added value of multi-tissue analysis in the identification of mosaicism in tumour predisposition syndromesL Damen, M F Broekema, M J Vogel, et al.
ESMO Open|July 15, 2023
Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studiesM V Dietz, J P van Kooten, M S Paats, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Gene|November 28, 1996
The aroA gene of Campylobacter jejuniM M Wösten, H J Dubbink, B A van der Zeijst
Nucleic Acids Research|November 25, 1993
Single point mutations in domain II of the yeast mitochondrial release factor mRF-1 affect ribosome bindingH J Pel, M Rep, H J Dubbink, et al.
Gene|December 2, 1999
An Sp1 binding site is essential for basal activity of the human prostate-specific transglutaminase gene (TGM4) promoterH J Dubbink, K B Cleutjens, H A van der Korput, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 6, 1999
Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution patternH J Dubbink, R F Hoedemaeker, T H van der Kwast, et al.
The Biochemical Journal|May 1, 1996
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminaseH J Dubbink, N S Verkaik, P W Faber, et al.
Genomics|August 29, 1998
The human prostate-specific transglutaminase gene (TGM4): genomic organization, tissue-specific expression, and promoter characterizationH J Dubbink, L de Waal, R van Haperen, et al.
Urology|May 20, 1998
Expression of prostatic factors measured by reverse transcription polymerase chain reaction in human papillomavirus type 18 deoxyribonucleic acid immortalized prostate cell linesP C Weijerman, Y Zhang, J Shen, et al.
The British Journal of Ophthalmology|October 31, 2020
Prognostic value of <i>TERT</i> promoter mutations in conjunctival melanomas in addition to clinicopathological featuresJ A van Ipenburg, N C Naus, H J Dubbink, et al.
Journal of Medical Genetics|February 17, 2026
End of a diagnostic odyssey: the added value of multi-tissue analysis in the identification of mosaicism in tumour predisposition syndromesL Damen, M F Broekema, M J Vogel, et al.
ESMO Open|July 15, 2023
Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studiesM V Dietz, J P van Kooten, M S Paats, et al.
Pageof 3